Navigation Links
Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
Date:3/11/2008

SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer, today announced that an abstract detailing results from the RAV12 Phase 1/2a trial has been accepted as a poster discussion presentation at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO). The presentation is scheduled for May 30, 2008. Dr. Nancy Lewis of the Fox Chase Cancer Center is the abstract's first author and will make the presentation on behalf of the study's participating investigators.

The study, which enrolled 53 patients with adenocarcinomas bearing the RAAG12 antigen, particularly those of gastrointestinal (GI) origin, was conducted at 5 institutions in the US, the Sarah Cannon Cancer Center in Nashville, TN; the Fox Chase Cancer Center in Philadelphia, PA; Premiere Oncology in Santa Monica, CA; the University of Miami Medical Center in Miami, FL; and the Georgetown University Medical Center in Washington, DC.

About GI Cancers

Adenocarcinomas are malignant tumors of the epithelial cells that line glands or viscera. They typically spread by way of the circulatory or lymphatic systems and are poorly treated after metastatic dissemination. More than 90 percent of colon, stomach and pancreatic tumor specimens express the RAV12-defined antigen, RAAG12. Adenocarcinomas arising elsewhere, such as breast, endometrial, ovarian, lung and prostate, display the antigen at lower frequency.

About RAV12

RAV12 is a novel, chimeric monoclonal antibody that is directed against a primate-specific glycotope (sugar structure) that is widely displayed on the surfaces of tumor cells, particularly those of gastrointestinal origin (gastroesophageal, pancreatic, and colorectal cancers). Preclinical studies have demonstrated that RAV12 may kill tumor cells in a number of ways: first, the antibody is directly c
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
2. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
3. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
4. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
5. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
8. Cynosure Announces Upcoming Investor Presentations at Cowen and Citi Investor Conferences
9. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
10. Mentice AB Announces Leadership Changes Within Its Worldwide Operations
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)IRVINE, Calif., Dec. 4 BlueFire Ethanol Fuels, Inc. (OTC Bulletin Board: BFRE), a company focused on changing the world,s transportation fuel paradigm through the production of ethanol from non-food
(Date:12/3/2009)DALLAS, Dec. 3 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a deb
(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
Breaking Biology Technology:BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3
...rporated (NYSE: DGX ), the nation,s leading provi...s, announced that it is scheduled to speak,at the ...day, January 8,2008, at the Westin St. Francis in ...resentation is scheduled to begin at 11:00 a.m. Ea...e during the conference and will be,available to r...
...CEPH) announced today that the presentation slides...Healthcare Conference are now available on the,"In...te at, http://www.cephalon.com . On Tuesday, Janua... CEO, will deliver a one hour presentation at the,...p.m. Eastern Time)., Live Web Cast and Archived R...
...-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products G...g,Corps Agro-technology Extended Terminal promulga... "Pen Duo Shou" and "Jin Peng Jia Bao", both of,wh...al fertilizer,certificate replaces the previous Te...rtificate., In 2007, Xinjiang Corps Agro-technolo...
Other Biology Technology:Quest Diagnostics to Speak at the 26th Annual JPMorgan Healthcare Conference 2Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available 2Kiwa Fertilizers Pass Independent Tests 2Kiwa Fertilizers Pass Independent Tests 3
(Date:12/3/2009)Contents of this message: , , Preliminary Press Conference Topics, Last Call! Press Field Trip to California Academy of Sciences museum, Attention PIOs: Sending Press Releases to Fall meeting, N
(Date:12/3/2009)Coral reef fish can undergo a personality change in warmer water, according to an intriguing new study suggesting that climate change may make some species more aggressive. , Experiments with two spe
(Date:12/3/2009)The UK leads the world when it comes to investment in energy efficient technologies research, but Engineering and Physical Sciences Research Council (EPSRC) Chief Executive Dave Delpy believes that mo
Breaking Biology News(10 mins):AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6Fish with attitude: Some like it hot 2Research is vital to a cleaner, greener, low carbon future 2Seven Tips for Safer Home Swimming Pools and Hot Tubs 52946 1Seven Tips for Safer Home Swimming Pools and Hot Tubs 52946 2Laureate Pharma Appoints Daniel E Leone as Vice President of Business Development 13233 1Laureate Pharma Appoints Daniel E Leone as Vice President of Business Development 13233 2Clear Choice Health Plans Selects Thomson Reuters to Deliver Healthcare Cost Information to Members and Exceed State Transparency Requirements 52939 1Clear Choice Health Plans Selects Thomson Reuters to Deliver Healthcare Cost Information to Members and Exceed State Transparency Requirements 52939 2Clear Choice Health Plans Selects Thomson Reuters to Deliver Healthcare Cost Information to Members and Exceed State Transparency Requirements 52939 3
... available in Spanish . , Arlington, Virginia ...at least some dogs, have to do it. , In the Cerra...nimal feces by scent are helping researchers monit...pir, giant anteater and maned wolf in and around E...st concentration of threatened species in Brazil. ...
... IMMEDIATE RELEASE , Identifying abnormal protei...teome Research , Researchers in Massachusetts ar...dical knowledge about the biochemical changes that...c retinopathy (DR) a leading cause of vision loss... the June 6 issue of ACS monthly Journal of Proteo...
...rchers at Columbia University Medical Center have ...roRNAs, a family of molecules that regulate expres...vioral and neuronal deficits associated with schiz...In the May 11 issue of Nature Genetics, Maria Kara... A. Gogos, M.D., Ph.D., associate professor of phy...
Other Biology News:Can feces save the species? 2Can feces save the species? 3American Chemical Society’s Weekly PressPac -- May 7, 2008 2American Chemical Society’s Weekly PressPac -- May 7, 2008 3American Chemical Society’s Weekly PressPac -- May 7, 2008 4American Chemical Society’s Weekly PressPac -- May 7, 2008 5American Chemical Society’s Weekly PressPac -- May 7, 2008 6American Chemical Society’s Weekly PressPac -- May 7, 2008 7American Chemical Society’s Weekly PressPac -- May 7, 2008 8Scientists dig deeper into the genetics of schizophrenia by evaluating microRNAs 2
WinMelt Software, PC and Windows from Bio-Rad
Mini-blot Trays from Bio-Rad
... SNPs, Polymorphic uses proven, validated Sanger d...alysis. We use high throughput capillary sequencin...nfirmed by sequencing in both directions. The use ...nformation, further confirming the location of the...
... PowerPac 3000 power supply is the most versatile ...sing, DNA sequencing, isotachophoresis, SDS-PAGE, ...estern blotting, and submerged gel nucleic acid se...power supply offers enough power to run the most d...
Biology Products: